JK
Jeff E. Knight
Chief Dev. & Operating Officer

Jeff E. Knight insider trades: Crinetics Pharmaceuticals (CRNX) stock sales

Chief Dev. & Operating Officer, Crinetics Pharmaceuticals Last trade Apr 8, 2026 17 Form 4 filings
$3.8M
Sold, last 12 months
2 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2022
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Jeff reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Apr 8, 2026CRNX↓ Sell$3.4M
Mar 16, 2026CRNX↓ Sell$370K
Mar 19, 2025CRNX↓ Sell$245K
Nov 22, 2024CRNX↓ Sell$28K
Jul 15, 2024CRNX↓ Sell$1.5M
Jun 26, 2024CRNX↓ Sell$42K
Mar 22, 2024CRNX↓ Sell$1.4M
Jul 26, 2022CRNX↓ Sell$24K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other CRNX insiders

Open-market trades in the last 12 months

About Jeff E. Knight's insider trades

Jeff E. Knight is Chief Dev. & Operating Officer at Crinetics Pharmaceuticals (CRNX). Since Jul 26, 2022, Jeff has reported no open-market purchases and 8 sales worth $7.0M on SEC Form 4. In the last 12 months: 2 sales ($3.8M).

Their filings also include grants and awards (7 filings), option exercises (3 filings), shares withheld for taxes (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CRNX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.